NasdaqCM - Delayed Quote USD

Gyre Therapeutics, Inc. (GYRE)

8.07
-0.37
(-4.38%)
At close: June 12 at 4:00:00 PM EDT
8.31
+0.24
+(2.97%)
After hours: June 12 at 6:35:42 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GYRE

Recent News: GYRE

View more
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
GlobeNewswire 2 days ago
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire 14 days ago
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire 21 days ago
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire 21 days ago
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
GlobeNewswire 21 days ago
Gyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)

Gyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)
Simply Wall St. last month
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire last month
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity

A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity
Simply Wall St. last month
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewswire 2 months ago
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
Simply Wall St. 2 months ago
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
GlobeNewswire 2 months ago
View more

Related Tickers

2160.T GNI Group Ltd.
3,595.00
-3.10%
 
TSBX Turnstone Biologics Corp.
0.3567
-0.92%
 
ATXS Astria Therapeutics, Inc.
5.60
-3.28%
 
FENC Fennec Pharmaceuticals Inc.
8.32
+1.46%
 
IGMS IGM Biosciences, Inc.
1.2100
-4.72%
 
LENZ LENZ Therapeutics, Inc.
29.58
-1.40%
 
4974.T Takara Bio Inc.
779.00
-1.39%
 
OLMA Olema Pharmaceuticals, Inc.
4.0600
-0.49%
 
4565.T Nxera Pharma Co., Ltd.
919.00
-3.77%
 
EMMA Emmaus Life Sciences, Inc.
0.0170
0.00%